NasdaqGS - Nasdaq Real Time Price USD

Biogen Inc. (BIIB)

193.18

-0.93

(-0.48%)

At close: April 23 at 4:00 PM EDT

193.45

+0.27

(+0.14%)

After hours: April 23 at 7:53 PM EDT

Should You Be Confident in Biogen (BIIB)?

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter 2024 investor letter. A copy of the same can be downloaded here. During the quarter the strategy returned 11.8% net of fees compared to the S&P 500’s 10.6% return. The outperformance of the portfolio can be attributed to selection and […]

Insider Monkey yesterday

BIIB
-0.48%
What's in Store for Biogen (BIIB) This Earnings Season?

Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.

Zacks 4 days ago

BIIB
-0.48%
Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.

Zacks 4 days ago

BIIB
-0.48%
Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?

Lilly is soon planning to ask global regulators to approve tirzepatide for sleep apnea treatment. Is Eli Lilly stock a buy?

Investor's Business Daily 5 days ago

LLY
+1.96%
NVO

BIIB
-0.48%
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 5 days ago

GILD
+0.12%
BIIB
-0.48%
Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 6 days ago

BIIB
-0.48%
Biogen Is Suffering From Doubts About the Future

A closer look at one of the leaders in the global multiple sclerosis therapeutics market

GuruFocus.com 11 days ago

BIIB
-0.48%
Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $214.83, denoting a -0.37% change from the preceding trading day.

Zacks 22 days ago

BIIB
-0.48%
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that Eisai submitted to the U.S. Food and Drug Administration (FDA) a Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: LEQEMBI®) intravenous (IV) maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer's disease (AD) in patients with

PR Newswire 23 days ago

BIIB
-0.48%
ESAIY

ESALF
Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investor's Business Daily 26 days ago

LLY
+1.96%
BIIB
-0.48%
PRTA
CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.

Zacks 28 days ago

BIIB
-0.48%
PRTA

ANIP
Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $216.69, moving -0.65% from the previous trading session.

Zacks 29 days ago

BIIB
-0.48%
^GSPC
Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

Zacks 29 days ago

LH

QGEN

BIIB
-0.48%
UPDATE 3-EU regulator delays decision on Eisai-Biogen Alzheimer's drug

The European Union's medicines regulator has delayed its decision on Eisai and partner Biogen's Alzheimer's disease drug that was expected this week, the Japanese company said on Friday. On Monday, the European Medicines Agency had said it would hold an oral hearing this week to discuss the drug, lecanemab, which has been under review in Europe since January 2023. Eisai said the delay was due to a EU court ruling last week, unrelated to the Alzheimer's drug, that had "implications on EMA's policy on the handling of competing interests of experts."

Reuters last month

BIIB
-0.48%
Hedge Funds and Insiders Are Buying These 10 Stocks

In this article, we will take a detailed look at Hedge Funds and Insiders Are Buying These 10 Stocks. For a quick overview of such stocks, read our article Hedge Funds and Insiders Are Buying These 5 Stocks. Stocks are moving higher after the Federal Reserve’s indication that it’s still eyeing three rate cuts this year. While many analysts […]

Insider Monkey last month

AIG

BX

WSC
Biogen, Moderna, and 6 More Healthcare Stocks That Wall Street Thinks Have Upside

After an abysmal 2023, healthcare stocks are nearly keeping pace with the broader market this year. The fund, which tracks healthcare stocks in the has returned 7.3% so far this year as of Tuesday’s market close—just a bit behind the broader index, which has returned 8.9%. Healthcare stocks fell deeply out of favor in 2023, amid a rush away from what had been thought of as defensive plays into hot tech stocks.

Barrons.com last month

BIIB
-0.48%
MRNA

PODD
Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today

Biogen Inc. (BIIB) reachead $219.40 at the closing of the latest trading day, reflecting a +0.04% change compared to its last close.

Zacks last month

BIIB
-0.48%
25 Most Stressed Cities in the United States

In this article, we will be taking a look at the 25 most stressed cities in the United States. If you do not want to learn about the global impact of stress and depression, head straight to the 5 Most Stressed Cities in the United States. In the bustling landscape of the United States, certain […]

Insider Monkey last month

SAGE

BIIB
-0.48%
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?

Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

BIIB
-0.48%
DCPH
Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know

Biogen Inc. (BIIB) concluded the recent trading session at $227.36, signifying a -1.18% move from its prior day's close.

Zacks last month

BIIB
-0.48%

Performance Overview

Return	BIIB	S&P 500
YTD	-25.35%	+6.30%
1-Year	-34.29%	+22.67%
3-Year	-25.41%	+22.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Biogen Inc. (BIIB)

Should You Be Confident in Biogen (BIIB)?

What's in Store for Biogen (BIIB) This Earnings Season?

Gear Up for Biogen (BIIB) Q1 Earnings: Wall Street Estimates for Key Metrics

Is Eli Lilly Stock A Buy After Weight-Loss Drug Succeeds In Sleep Apnea Patients?

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

Biogen Is Suffering From Doubts About the Future

Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know

Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

Biogen Inc. (BIIB) Dips More Than Broader Market: What You Should Know

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

UPDATE 3-EU regulator delays decision on Eisai-Biogen Alzheimer's drug

Hedge Funds and Insiders Are Buying These 10 Stocks

Biogen, Moderna, and 6 More Healthcare Stocks That Wall Street Thinks Have Upside

Here's Why Biogen Inc. (BIIB) Gained But Lagged the Market Today

25 Most Stressed Cities in the United States

Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?

Biogen Inc. (BIIB) Stock Falls Amid Market Uptick: What Investors Need to Know

Performance Overview